Management of hepatocellular carcinoma with portal vein thrombosis

Table 1 Up-to-date summary of management options for hepatocellular carcinoma with portal vein thrombosis

	Survival data (mo)					Adverse effects	Key references	Additional comments
	Overall survival	Main PVTT	Branch PVTT	CP-A	CP-B
Supportive care	2-4						Schoniger et al[12], Minagawa et al[9], Llovet et al[10]
Surgical resection	9-33	9-10				0%-6% operative mortality	Lau et al[13], Shi et al[17], Chen et al[18], Lin et al[21]	Employed in select centers
Sorafenib	6-8			8.1		skin reaction, diarrhea, fatigue	Llovet et al[27], Cheng et al[29]	Recommended by AASLD and EASL guidelines;
								Dose reduction in 25%, interruption in 44%
XRT	9.6					radiation induced liver disease	Toya et al[53]	Investigational
TACE	7-10	5.3	10.2	7.4	2.8	liver failure, postembolization syndrome	Pinter et al[40], Chung et al[41], Luo et al[43], Xue et al[48]	Lowest risk with nonocclusive thrombus, cavernous transformation, superselective TACE
Y-90 SIRT	5-17	9	17	10.4	5.6	fatigue, hyperbilirubinemia, GI ulceration	Salem et al[70], Hilgard et al[69], Sangro et al[71]	Currently, PVT is one of the indications for Y90